BROAD-SPECTRUM • HOST-DIRECTED ANTIVIRALS
Transformational Broad-Spectrum Antiviral Platform
Making a paradigm shift in antiviral drug treatment
ViroCarb is pioneering a new class of broad-spectrum, host-directed antivirals designed to treat many viral infections — including future threats — with a single therapeutic approach.
Supported by over a decade of solid peer-reviewed research and preclinical studies
Scroll
THE NETWORK • PARTNERSHIPS
Strategic partnerships powering ViroCarb R&D.
Through its partnership with the University of Toronto, ViroCarb is turning breakthrough science into market-ready impact by leveraging world-class expertise, advanced facilities, government-backed funding, and a lean expert network
A strong, lean network that reduces costs and accelerates early-stage technology development.
GOVERNMENT COLLABORATION
National Research Council of Canada
- Supports in vitro and in vivo experimental research on key pathogenic viruses.
- Provides access to dedicated government-backed research funding.
CRO RESEARCH NETWORK
Specialized contract research
- Global access to synthetic chemistry, toxicology, and clinical CROs.
- Certified facilities and expertise, delivered cost-effectively.
PROFESSIONAL SERVICES
Legal, regulatory & IP
- Strategic collaborations with leading legal, regulatory, and IP firms.
- Protects and advances the ViroCarb portfolio as it scales.
Join the Paradigm Shift.
ViroCarb is actively seeking investment partners for its Seed Round. Reach out to learn more about the science and opportunity.